Trial · NCT01556763
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. | Screening (Day -5 for continuous cardiac monitoring) to Day 22 | All randomized patients who ingested at least one dose of study drug or placebo. | participants | NUMBER |
| PRIMARY | EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole | Days 1 and 21 | All patients receiving aripiprazole. | pg/mL | MEAN |
| PRIMARY | EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole | Days 1 and 21 | All patients receiving aripiprazole. | hr | MEDIAN |
| PRIMARY | EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole | Days 1 and 21 | All patients receiving aripiprazole. | pg*hr/mL | MEAN |
| PRIMARY | EVP-6124 Half-life (T[1/2]), Patients on Aripiprazole | Days 1 and 21 | Patients receiving aripiprazole for whom blood samples were available for analysis. | hr | MEAN |
| PRIMARY | EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Paliperidone/Risperidone | Days 1 and 21 | All patients receiving paliperidone/risperidone. | pg/mL | MEAN |
| PRIMARY | EVP-6124 Time to Maximum Concentration (Tmax), Patients on Paliperidone/Risperidone | Days 1 and 21 | All patients receiving paliperidone/risperidone. | hr | MEDIAN |
| PRIMARY | EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Paliperidone/Risperidone | Days 1 and 21 | All patients receiving paliperidone/risperidone. | pg*hr/ml | MEAN |
| PRIMARY | EVP-6124 Half-life (T[1/2]), Patients on Paliperidone/Risperidone | Days 1 and 21 | Patients receiving paliperidone/risperidone for whom blood samples were available for analysis. | hr | MEAN |
| SECONDARY | N100 Gating Ratio | Days -1 to 20 | Subjects providing valid and measurable N100 responses. | ratio | MEAN |
| SECONDARY | P50 Amplitude Difference | Days -1 to 20 | Subjects providing valid and measurable P50 responses. | microvolts | MEAN |
| SECONDARY | MMN Summed Amplitude | Days -1 to 20 | Subjects providing valid and measurable MMN responses. | microvolts | MEAN |
| SECONDARY | P300 Peak Amplitude | Days -1 to 20 | Subjects providing valid and measurable P300 responses. | microvolts | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01556763/outcomes